HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Primary myelofibrosis — Clinical Guidelines

Overview

Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, leading to extramedullary hematopoiesis, splenomegaly, and cytopenias 6.

Diagnosis

Clinical Presentation: Symptoms include splenomegaly, constitutional symptoms, anemia, leukocytosis, and thrombocytosis 6.

Laboratory Tests: Elevated white blood cell count, anemia, and thrombocytosis; bone marrow biopsy showing fibrosis and megakaryocyte atypia 6.

Risk Stratification Models: Use of models like DIPSS+, MIPSS70+, and GIPSS for prognostic assessment 1.

Imaging: MRI can show decreased bone marrow signal intensity due to fibrosis 18.

Management

First-Line Treatment:

- Ruxolitinib: Effective for reducing spleen size and symptom burden; monitor for anemia and need for red blood cell transfusions 2 3.

Adjunctive Treatments:

- Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Considered for younger patients with high-risk disease, though practices vary widely 4. - Navitoclax Combination: Shows efficacy and safety when combined with ruxolitinib 2. - Interferon-α (IFN-α): Limited evidence; role remains uncertain 8.

Special Populations

Elderly Patients: Management focuses on symptom control and risk stratification; ruxolitinib is commonly used 6.

Comorbidities: Anemia and bleeding risks (e.g., lupus anticoagulant) require careful monitoring and management 19 3.

Key Recommendations

Utilize risk stratification models such as DIPSS+ for prognostic assessment and guiding treatment decisions (Evidence: Strong 1).

Initiate ruxolitinib for symptom control and spleen size reduction in symptomatic patients with myelofibrosis (Evidence: Moderate 2 3).

Consider allogeneic hematopoietic cell transplantation in younger patients with high-risk disease, acknowledging variable clinical practices (Evidence: Moderate 4).

Closely monitor for and manage anemia and transfusion requirements during ruxolitinib therapy (Evidence: Moderate 3).

Evaluate the potential role of novel agents like navitoclax in combination therapy for enhanced efficacy (Evidence: Weak 2).

References

1 Tefferi A, Vannucchi AM. Risk models in myelofibrosis-the past, present, and future. American journal of hematology 2024. link 2 . Ruxolitinib with Navitoclax Is Efficacious and Safe in Myelofibrosis. Cancer discovery 2022. link 3 Jung EH, Hong J, Kim SY, Park Y, Yuh YJ, Mun YC et al.. Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology. Clinical lymphoma, myeloma & leukemia 2022. link 4 McLornan DP, Sirait T, Hernández-Boluda JC, Czerw T, Hayden P, Yakoub-Agha I. European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. Current research in translational medicine 2021. link 5 Wada T, Yano Y, Yamamoto A, Kinoshita M, Yasutomi E, Hatazawa Y et al.. Jejunal variceal rupture in a patient with myelofibrosis: a case report. Clinical journal of gastroenterology 2021. link 6 Sliwa T, Beham-Schmid C, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K et al.. Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. Wiener klinische Wochenschrift 2017. link 7 Mascarenhas J. Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis. Hematology. American Society of Hematology. Education Program 2015. link 8 Nguyen HM, Kiladjian JJ. Is there a role for the use of IFN-α in primary myelofibrosis?. Hematology. American Society of Hematology. Education Program 2012. link 9 Gualco G, Ojopi EB, Chioato L, Cordeiro DL, Negretti F, Bacchi CE. Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature. Applied immunohistochemistry & molecular morphology : AIMM 2010. link 10 Srinivasaiah N, Zia MK, Muralikrishnan V. Peritonitis in myelofibrosis: a cautionary tale. Hepatobiliary & pancreatic diseases international : HBPD INT 2010. link 11 Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B et al.. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005. link 12 Liu TT, Chen JB, Chen WJ, Kuo CY, Lee CT. Idiopathic myelofibrosis associated with renal extramedullary hematopoiesis and nephrotic syndrome: case report. Chang Gung medical journal 2000. link 13 Seelen MA, de Meijer PH, Posthuma EF, Meinders AE. Myelofibrosis and idiopathic thrombocytopenic purpura. Annals of hematology 1997. link 14 Sandberg AA, Morgan R, Betz J, Hashimi M, Vye MV. Unusual and unrelated polyclonality in a case of myeloid disease. Cancer genetics and cytogenetics 1996. link00258-8) 15 Asakura S, Colby TV. Agnogenic myeloid metaplasia with extramedullary hematopoiesis and fibrosis in the lung. Report of two cases. Chest 1994. link 16 Benbassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in patients with advanced agnogenic myeloid metaplasia. American journal of hematology 1990. link 17 Gruber A, Osby E. Osteolytic lesions in idiopathic myelofibrosis. Medical oncology and tumor pharmacotherapy 1987. link 18 Lanir A, Aghai E, Simon JS, Lee RG, Clouse ME. MR imaging in myelofibrosis. Journal of computer assisted tomography 1986. link 19 Bernhardt B, Valletta M. Lupus anticoagulant in myelofibrosis. The American journal of the medical sciences 1976. link

Primary myelofibrosis